Literature DB >> 12612320

Juvenile myoclonic epilepsy: under-appreciated and under-diagnosed.

R Renganathan1, N Delanty.   

Abstract

Juvenile myoclonic epilepsy (JME) is a hereditary, idiopathic, generalised epilepsy and is found in 5%-11% of patients with epilepsy. It is characterised by myoclonic jerks, occasional generalised tonic-clonic seizures, and sometimes absence seizures. JME continues to be under-appreciated and under-diagnosed. Accurate diagnosis is important as it usually responds well to treatment with appropriate anticonvulsants and misdiagnosis often results in unnecessary morbidity. In addition lifelong therapy is usually indicated as the natural history is one of relapse off treatment, even after a prolonged seizure-free period.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12612320      PMCID: PMC1742603          DOI: 10.1136/pmj.79.928.78

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  18 in total

1.  Exacerbation of juvenile myoclonic epilepsy with lamotrigine.

Authors:  A Biraben; H Allain; J M Scarabin; S Schück; G Edan
Journal:  Neurology       Date:  2000-12-12       Impact factor: 9.910

2.  A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group.

Authors:  V Biton; G D Montouris; F Ritter; J J Riviello; R Reife; P Lim; G Pledger
Journal:  Neurology       Date:  1999-04-22       Impact factor: 9.910

3.  Refined mapping of the epilepsy susceptibility locus EJM1 on chromosome 6.

Authors:  T Sander; B Bockenkamp; T Hildmann; R Blasczyk; R Kretz; T F Wienker; A Volz; B Schmitz; G Beck-Mannagetta; O Riess; J T Epplen; D Janz; A Ziegler
Journal:  Neurology       Date:  1997-09       Impact factor: 9.910

4.  No evidence for a major susceptibility locus for juvenile myoclonic epilepsy on chromosome 15q.

Authors:  M Durner; S Shinnar; S R Resor; S L Moshe; D Rosenbaum; J Cohen; C Harden; H Kang; S Hertz; S Wallace; D Luciano; K Ballaban-Gil; D A Greenberg
Journal:  Am J Med Genet       Date:  2000-02-07

5.  Abnormal cerebral structure in juvenile myoclonic epilepsy demonstrated with voxel-based analysis of MRI.

Authors:  F G Woermann; S L Free; M J Koepp; S M Sisodiya; J S Duncan
Journal:  Brain       Date:  1999-11       Impact factor: 13.501

6.  MR spectroscopy shows reduced frontal lobe concentrations of N-acetyl aspartate in patients with juvenile myoclonic epilepsy.

Authors:  I Savic; A Lekvall; D Greitz; G Helms
Journal:  Epilepsia       Date:  2000-03       Impact factor: 5.864

7.  Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy?

Authors:  P Genton; P Gelisse; P Thomas; C Dravet
Journal:  Neurology       Date:  2000-10-24       Impact factor: 9.910

8.  Clinical factors of drug resistance in juvenile myoclonic epilepsy.

Authors:  P Gelisse; P Genton; P Thomas; M Rey; J C Samuelian; C Dravet
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-02       Impact factor: 10.154

9.  Clinical and EEG asymmetries in juvenile myoclonic epilepsy.

Authors:  M E Lancman; J J Asconapé; J K Penry
Journal:  Epilepsia       Date:  1994 Mar-Apr       Impact factor: 5.864

10.  The use of lamotrigine in juvenile myoclonic epilepsy.

Authors:  N Buchanan
Journal:  Seizure       Date:  1996-06       Impact factor: 3.184

View more
  2 in total

1.  Cognitive Dysfunction in Juvenile Myoclonic Epilepsy (JME) - A Tertiary Care Center Study.

Authors:  Tanushree Chawla; Neera Chaudhry; Vinod Puri
Journal:  Ann Indian Acad Neurol       Date:  2021-02-16       Impact factor: 1.383

2.  Levetiracetam in the treatment of epilepsy.

Authors:  Bassel Abou-Khalil
Journal:  Neuropsychiatr Dis Treat       Date:  2008-06       Impact factor: 2.570

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.